Tag: Libbs
Biocon & Mylan’s biosimilar ‘Trastuzumab’ gets approval from Brazilian regulator
Co-developed by Biocon and Mylan, this is the first biosimilar Trastuzumab to be approved in Brazil and is indicated for the treatment of overexpressing HER2positive metastatic breast cancer. The product will be marketed by the Libbs Farmaceutica........